The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
|ClinicalTrials.gov Identifier: NCT00002396|
Recruitment Status : Unknown
Verified November 1999 by NIH AIDS Clinical Trials Information Service.
Recruitment status was: Active, not recruiting
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Tenofovir disoproxil fumarate||Phase 1|
In this double-blind, placebo-controlled study, a total of 60 patients are randomized to receive PMPA prodrug at 1 of 5 doses or matching placebo tablets.
Part A (Days 1-7): Patients receive a single dose of PMPA prodrug or matching placebo tablets administered orally followed by a 1-week observation period. Patients who complete Part A without a dose-limiting toxicity begin Part B.
Part B (Days 8-35): Patients receive either PMPA prodrug or matching placebo tablets administered orally qd for 4 weeks at the same dosage level administered in Part A.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Official Title:||A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Activity of 9-[2-(R)-[[Bis[[(Isopropoxycarbonyl)- Oxy]Methoxy]Phosphinoyl]Methoxy]Propyl]Adenine Fumarate (PMPA Prodrug) in HIV-Infected Patients|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002396
|United States, California|
|San Francisco Gen Hosp|
|San Francisco, California, United States, 94115|
|United States, Maryland|
|Johns Hopkins Hosp|
|Baltimore, Maryland, United States, 21205|
|United States, Washington|
|Univ of Washington / AIDS Clinical Trial Unit|
|Seattle, Washington, United States, 98104|